外科理论与实践 ›› 2024, Vol. 29 ›› Issue (05): 414-425.doi: 10.16139/j.1007-9610.2024.05.09
收稿日期:
2024-08-25
出版日期:
2024-09-25
发布日期:
2025-01-23
通讯作者:
郑鸿,E-mail:zzhzhzjy@163.com基金资助:
CHU Yudan, SUN Haidong, CUI Ran, ZHENG Hong()
Received:
2024-08-25
Online:
2024-09-25
Published:
2025-01-23
摘要:
目的:建立基于双硫死亡相关长链非编码RNA(LncRNA)的评分模型并探索LncRNA-SNHG4促进胃癌进展的机制。方法:首先基于TCGA数据库分析胃癌中双硫死亡基因的多组学特征,进一步筛选双硫死亡相关的LncRNA(DRLncs),构建双硫死亡相关基因风险评估(DRG-RS)模型,预测胃癌病人的总生存(Overall survival, OS)及与临床特征之间的关联,分析高、低风险组之间差异基因、功能富集和化疗疗效的相关性。通过CCK-8实验和迁移实验检测证实LncRNA-SNHG4促进胃癌细胞的恶性表型。通过免疫印迹实验检测LncRNA-SNHG4调控的信号通路。结果:成功构建包含8种DRLncs的DRG-RS,其预测胃癌病人OS的表现良好。DRG-RS模型与肿瘤相关信号通路、胃癌病人临床特征和药物敏感性之间显著相关。LncRNA-SNHG4在胃癌组织中表达显著升高,LncRNA-SNHG4显著促进胃癌细胞的增殖和迁移能力,并激活胃癌细胞中Wnt信号通路。结论:本研究构建的DRG-RS模型可对胃癌预后进行分层,且与胃癌病人的恶性特征和化疗疗效密切相关。LncRNA-SNHG4在胃癌组织中表达明显升高,且LncRNA-SNHG4通过激活Wnt信号通路促进胃癌细胞的恶性表型,在胃癌进展中可能发挥重要作用。
中图分类号:
褚玉丹, 孙海东, 崔冉, 郑鸿. 双硫死亡相关LncRNA在胃癌中的表达及其临床意义[J]. 外科理论与实践, 2024, 29(05): 414-425.
CHU Yudan, SUN Haidong, CUI Ran, ZHENG Hong. Expression and clinical significance of disulfidptosis-related LncRNA in gastric cancer[J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 414-425.
[1] | TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics,2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. |
[2] | GUAN W L, HE Y, XU R H. Gastric cancer treatment: recent progress and future perspectives[J]. J Hematol Oncol, 2023, 16(1):57. |
[3] |
WEI L, SUN J, ZHANG N, et al. Noncoding RNAs in gastric cancer: implications for drug resistance[J]. Mol Cancer, 2020, 19(1):62.
doi: 10.1186/s12943-020-01185-7 pmid: 32192494 |
[4] | LE J, PAN G, ZHANG C, et al. Targeting ferroptosis in gastric cancer: strategies and opportunities[J]. Immunol Rev, 2024, 321(1):228-245. |
[5] |
NEWTON K, STRASSER A, KAYAGAKI N, et al. Cell death[J]. Cell, 2024, 187(2):235-256.
doi: 10.1016/j.cell.2023.11.044 pmid: 38242081 |
[6] |
HANAHAN D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1):31-46.
doi: 10.1158/2159-8290.CD-21-1059 pmid: 35022204 |
[7] |
CARNEIRO B A, EL-DEIRY W S. Targeting apoptosis in cancer therapy[J]. Nat Rev Clin Oncol, 2020, 17(7):395-417.
doi: 10.1038/s41571-020-0341-y pmid: 32203277 |
[8] | PISTRITTO G, TRISCIUOGLIO D, CECI C, et al. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies[J]. Aging (Albany NY), 2016, 8(4):603-619. |
[9] |
ZHANG C, LIU X, JIN S, et al. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance[J]. Mol Cancer, 2022, 21(1):47.
doi: 10.1186/s12943-022-01530-y pmid: 35151318 |
[10] | GAO W, WANG X, ZHOU Y, et al. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy[J]. Signal Transduct Target Ther, 2022, 7(1):196. |
[11] | FAUBERT B, SOLMONSON A, DEBERARDINIS R J. Metabolic reprogramming and cancer progression[J]. Science, 2020, 368(6487):eaaw5473. |
[12] |
MAO C, WANG M, ZHUANG L, et al. Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond[J]. Protein Cell, 2024, 15(9):642-660.
doi: 10.1093/procel/pwae003 |
[13] |
ZHENG P, ZHOU C, DING Y, et al. Disulfidptosis: a new target for metabolic cancer therapy[J]. J Exp Clin Cancer Res, 2023, 42(1):103.
doi: 10.1186/s13046-023-02675-4 pmid: 37101248 |
[14] |
XIAO F, LI H L, YANG B, et al. Disulfidptosis: a new type of cell death[J]. Apoptosis, 2024, 29(9-10):1309-1329.
doi: 10.1007/s10495-024-01989-8 pmid: 38886311 |
[15] | BRIDGES M C, DAULAGALA A C, KOURTIDIS A. LNCcation: lncRNA localization and function[J]. J Cell Biol, 2021, 220(2):e202009045. |
[16] | WU Y, WEN X, XIA Y, et al. LncRNAs and regulated cell death in tumor cells[J]. Front Oncol, 2023,13:1170336. |
[17] | WANG R, YU X, YE H, et al. LncRNA FAM83H-AS1 inhibits ferroptosis of endometrial cancer by promoting DNMT1-mediated CDO1 promoter hypermethylation[J]. J Biol Chem, 2024, 300(9):107680. |
[18] | LIU S, ZHENG Y, LI S, et al. Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses[J]. J Cancer Res Clin Oncol, 2023, 149(18):16851-16867. |
[19] | XU K, ZHANG Y, YAN Z, et al. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which MSH3 is a key gene during disulfidptosis[J]. Front Immunol, 2023,14:1205250. |
[20] |
CHENG J, MA H, YAN M, et al. THAP9-AS1/miR-133b/SOX4 positive feedback loop facilitates the progression of esophageal squamous cell carcinoma[J]. Cell Death Dis, 2021, 12(4):401.
doi: 10.1038/s41419-021-03690-z pmid: 33854048 |
[21] | JIA W, ZHANG J, MA F, et al. Long noncoding RNA THAP9-AS1 is induced by Helicobacter pylori and promotes cell growth and migration of gastric cancer[J]. Onco Targets Ther, 2019,12:6653-6663. |
[22] |
DONG Q, QIU H, PIAO C, et al. LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA network[J]. J Exp Clin Cancer Res, 2023, 42(1):209.
doi: 10.1186/s13046-023-02774-2 pmid: 37596700 |
[1] | 陈长强, 严晓伟, 胡皆乐, 包皙婷, 项明, 姜松耀. 血清中PD-L1含量与胃癌病人预后的关系[J]. 外科理论与实践, 2024, 29(03): 230-235. |
[2] | 龚婷婷, 钱爱华, 陈希. 个体化预测早期胃癌内镜黏膜下剥离术后迟发性出血风险的列线图模型构建[J]. 外科理论与实践, 2024, 29(03): 236-242. |
[3] | 徐珊, 徐超. 老年胃癌整体评估及系统治疗现状[J]. 内科理论与实践, 2024, 19(03): 193-196. |
[4] | 朱正纲. 联合抗血管生成、免疫检查点抑制剂与化疗在局部进展期胃癌新辅助治疗中的临床意义[J]. 外科理论与实践, 2024, 29(02): 132-137. |
[5] | 吴熊焰, 李臻, 俞振佳, 苏丽萍. 假基因FMO6P抑制胃癌侵袭转移作用及其机制探索[J]. 外科理论与实践, 2024, 29(02): 161-169. |
[6] | 于素悦, 陆爱国. 保留幽门的胃切除术在早期胃癌外科治疗中的应用及相关指南共识解读[J]. 外科理论与实践, 2024, 29(01): 81-86. |
[7] | 张培婵, 罗春阳, 吴文雅, 吴震峰, 曹勤洪, 陈彻, 吴晓宇, 姚学权, 刘福坤. 基于倾向评分匹配法评估进展期胃癌合并同时性原发食管癌综合治疗的临床疗效[J]. 外科理论与实践, 2023, 28(06): 551-555. |
[8] | 李一林, 陈杨, 李艳艳, 冯旭娇, 章程, 李健, 沈琳. 循环肿瘤细胞检测在常见恶性肿瘤精准医学中的应用和展望[J]. 诊断学理论与实践, 2023, 22(04): 332-340. |
[9] | 严超, 陆晟, 燕敏, 朱正纲. 《日本胃癌治疗指南2021(第6版)》解读及瑞金实践[J]. 外科理论与实践, 2023, 28(04): 326-354. |
[10] | 孙祺, 黄文博, 何炳良, 刘畅, 徐宇航, 赵伟. 预防性腹腔热灌注化疗对局部进展期胃癌根治术后病人预后改善的有效性研究[J]. 外科理论与实践, 2023, 28(04): 366-370. |
[11] | 孙强, 姚骏, 张鑫, 杜杉珊, 王伟军. 近端胃切除抗反流消化道重建方式的研究进展[J]. 外科理论与实践, 2023, 28(04): 388-393. |
[12] | 胡文庆, 杨垠浩, 崔鹏, 魏伟. 食管胃结合部腺癌腹腔镜经腹-左膈肌路径近端胃加食管下段切除高位消化道重建现状[J]. 外科理论与实践, 2023, 28(03): 226-232. |
[13] | 燕速, 郑民华. 中国单孔及减孔腹腔镜胃癌手术实践[J]. 外科理论与实践, 2023, 28(03): 233-239. |
[14] | 颜凌, 王凌云, 陈勇, 杜联军. 双能CT图像深度学习重建算法在胃癌术前T分期中的应用[J]. 诊断学理论与实践, 2023, 22(02): 154-159. |
[15] | 徐凯, 李百文. 早期胃癌及胃癌前病变的内镜黏膜下剥离术治疗[J]. 内科理论与实践, 2023, 18(02): 102-106. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||